Effectiveness and safety of mirikizumab in patients with moderate-to-severe ulcerative colitis: the miri real multicenter study - PubMed
3 hours ago
- #mirikizumab
- #ulcerative colitis
- #real-world study
- Mirikizumab, targeting IL-23 p19, was evaluated in a real-world study of 236 moderate-to-severe ulcerative colitis patients, mostly with prior advanced therapy exposure.
- Clinical remission rates were 46.6% at week 12 and 55.5% at week 24, with significant improvements in partial Mayo score and endoscopic remission (38% at week 24).
- Intestinal ultrasound remission became significant at week 24, while bowel urgency and fecal calprotectin improved significantly at both timepoints.
- Effectiveness was similar in biologic-naive and biologic-exposed patients, with low discontinuation rates, infrequent non-serious adverse events, and no clinically relevant liver test changes.
- The study supports mirikizumab's effectiveness and safety in routine care over 24 weeks, highlighting selective IL-23 inhibition as a viable treatment option.